Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T. Tak PP, et al. Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19. Ann Rheum Dis. 2012. PMID: 22012969 Free PMC article. Clinical Trial.
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.
Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, van Tubergen A, Janssen M, de Hair M, Hansson M, de Vries N, Zwinderman AH, Tak PP. Gerlag DM, et al. Among authors: tak pp. Ann Rheum Dis. 2019 Feb;78(2):179-185. doi: 10.1136/annrheumdis-2017-212763. Epub 2018 Dec 1. Ann Rheum Dis. 2019. PMID: 30504445 Free PMC article. Clinical Trial.
Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire.
Pollastro S, Klarenbeek PL, Doorenspleet ME, van Schaik BDC, Esveldt REE, Thurlings RM, Boumans MJH, Gerlag DM, Tak PP, Vos K, Baas F, van Kampen AHC, de Vries N. Pollastro S, et al. Among authors: tak pp. Ann Rheum Dis. 2019 Oct;78(10):1339-1345. doi: 10.1136/annrheumdis-2018-214898. Epub 2019 Jun 19. Ann Rheum Dis. 2019. PMID: 31217169 Free PMC article.
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H. Behrens F, et al. Among authors: tak pp. Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17. Ann Rheum Dis. 2015. PMID: 24534756 Free PMC article. Clinical Trial.
602 results